We have furthermore elucidated regulation of BBB integrity through the iron dependent HIF2α—Ve-cadherin pathway and that the FDA approved DFO used to treat acute iron poisoning and hemochromatosis in clinic [121], attenuates damage to BLEC viability and barrier integrity by upregulating this pathway (Figure 6A). The gene discussed is CDH5; the disease is hemochromatosis type 1.